Rentschler Biopharma Completes Acquisition of US Manufacturing Site

Rentschler Biopharma, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, completed the acquisition of a manufacturing facility from an affiliate of Shire, the company announced in a January 3, 2019 press release. The 93,000-ft² site with approximately 70 employees is located near Boston in Milford, MA, and it is the German company’s first manufacturing facility in the United States. Under the terms of the agreement, Rentschler Biopharma will continue to manufacture for Shire at the site.

“The acquisition of this modern facility fits perfectly with our strategy to further strengthen and secure our world-class CDMO position in a growing and changing market. The US is a key market for Rentschler Biopharma, and this site gives us a firm foothold in this important area of growth, enabling us to better meet our clients’ needs,” said Frank Mathias, CEO of Rentschler Biopharma, in the press release.

Dr. Ralf Otto, COO of Rentschler Biopharma, added: “We will continue to make investments in our business to ensure we have the advanced technologies to remain an innovation leader in the field and the capacity to remain competitive and grow with our clients. This includes future plans to qualify the Milford site as a multi-product manufacturing facility.”